Spots Global Cancer Trial Database for A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
Official Title: A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Study ID: NCT00445198
Interventions
Study Description
Brief Summary: The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of ABT-263 with the objective of defining the dose limiting toxicity and maximum tolerated dose. (This portion of the study is complete). The Phase 2a portion of the study will evaluate ABT-263 at the defined recommended Phase 2 dose to obtain additional safety information and a preliminary assessment of efficacy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Site Reference ID/Investigator# 13605, Peoria, Arizona, United States
Site Reference ID/Investigator# 5261, Phoenix, Arizona, United States
Site Reference ID/Investigator# 11942, Los Angeles, California, United States
Site Reference ID/Investigator# 4718, Sacramento, California, United States
Site Reference ID/Investigator# 3755, Aurora, Colorado, United States
Site Reference ID/Investigator# 8324, Atlanta, Georgia, United States
Site Reference ID/Investigator# 2623, Chicago, Illinois, United States
Site Reference ID/Investigator# 2625, Baltimore, Maryland, United States
Site Reference ID/Investigator# 12343, Bethesda, Maryland, United States
Site Reference ID/Investigator# 11941, Boston, Massachusetts, United States
Site Reference ID/Investigator# 2626, Boston, Massachusetts, United States
Site Reference ID/Investigator# 4934, Charlotte, North Carolina, United States
Site Reference ID/Investigator# 2624, Nashville, Tennessee, United States
Site Reference ID/Investigator# 6650, Tacoma, Washington, United States
Site Reference ID/Investigator# 7493, Edmonton, , Canada
Site Reference ID/Investigator# 7635, Ottawa, , Canada
Site Reference ID/Investigator# 18541, Leicester, , United Kingdom
Site Reference ID/Investigator# 2622, Manchester, , United Kingdom
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
